Pneumococcal 23-valent vaccine - Sinovac Biotech

Drug Profile

Pneumococcal 23-valent vaccine - Sinovac Biotech

Alternative Names: 23-valent pneumococcal polysaccharide vaccine - Sinovac Biotech; 23-valent PPV - Sinovac

Latest Information Update: 17 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Sinovac Biotech
  • Class Pneumococcal vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Pneumococcal infections

Most Recent Events

  • 24 Aug 2017 Phase-III development is ongoing in China (Sinovac Biotech pipeline, August 2017)
  • 03 Aug 2017 Preregistration for Pneumococcal infections (In adolescents, In children, In the elderly, Prevention, In adults) in China (IM)
  • 01 Feb 2017 Sinovac Biotech complete a phase III trial in Pneumococcal infections (In children, In Adolescents, In adults, In the elderly, Prevention) in China (IM) (NCT02451969)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top